Pesticide disrupts neuronal potentiation
The pesticide deltamethrin is widely considered a safer alternative to other chemicals, such as organophosphates due to being less toxic to mammals. However, previous studies in mice showed that deltamethrin exposure at early stages of development can lead to neuronal toxicity, but scientists do not understand the mechanism involved. Therefore, Leandra Koff and a team led by Fernanda Laezza from the Sealy Center of Environmental Health & Medicine at the University of Texas Medical Branch and colleagues in the U.S. investigated how deltamethrin induces neuronal toxicity and published their results in Molecular & Cellular Proteomics.

The team focused on brain-derived extracellular vesicles, or BDEVs, structures that transport molecules, such as signaling proteins, between cells in the brain. Because changes in the BDEV proteome can be a sign of disease, the team used a mass spectrometry–based approach to compare the protein content of BDEVs in mice exposed to deltamethrin and controls. They found several differentially expressed proteins between the two groups. Some alterations are associated with neuronal structure, transport and long-term potentiation, which promotes synaptic connections and plays a role in learning and memory. These proteomic differences could be one explanation for neuronal toxicity due to impaired nutrient transport and growth.
BDEV protein levels could be used as biomarkers to evaluate the risk of neurodevelopmental disorders. More research is needed to understand how these proteins disrupt neuronal function at later stages of development.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.